CSBR
Champions Oncology·NASDAQ
--
--(--)
Market Open: --
--
--(--)
Pre-Market: --
Signals Analysis
Bullish signal 3
Bearish signal 1
High Gross Profit Margin
Significant Net Income Growth
EPS Beats Expectation
Price Hits 52-week Low
Key Stats
0.0000DAY`S RANGE0.0000
0.000052 WK RANGE0.0000
0.0000
0.0000
--
--
--
--
--
--
--
--
--
--
--
--
--
--
0.0000
0.0000
0.0000
0.0000
About CSBR
Champions Oncology, Inc.
A leading global technology-enabled biotech company that transforming drug discovery through innovative AI-driven pharmaco-pheno-multiomic integration
Pharmaceutical
06/04/1985
08/21/2015
NASDAQ Stock Exchange
213
04-30
Common stock
One University Plaza, Suite 307, Hackensack, New Jersey 07601
--
Champions Oncology, Inc. was incorporated on June 4, 1985 under the laws of the State of Delaware. The company is a technology-enabled research organization dedicated to creating transformative technology solutions for drug discovery and development. The company's research center consists of a comprehensive set of computational and experimental research platforms. The company's pharmacology, biomarkers and data platforms are designed to facilitate drug discovery and development at lower cost and faster speed. These include in vivo studies that rely on implanting multiple tumors in mice and testing treatments of interest to these tumors. The Company is engaged in the development and sales of advanced technology solutions and products, personalizing the development and use of oncology drugs through their Translational Oncology Solutions (" TOS "). The technology includes computing-based discovery platforms, unique oncology software solutions, and innovative and proprietary experimental tools such as in vivo, in vitro and biomarker platforms.
Earnings Call
Q1/2026
Estimate EPS-0.01
Actual EPS0.02
Estimate Revenue13.51M
Actual Revenue14.00M
Champions Oncology's Q1 2026: Contradictions Emerge on Data Licensing Traction, Revenue Outlook, and Funding Environment
Sep 15,2025 10:27
Earnings Decrypt
Earnings Decrypt
Company Financials
EPS
CSBR has released its 2026 Q1 earnings. EPS was reported at 0.02, versus the expected -0.01, beating expectations. The chart below visualizes how CSBR has performed over recent quarters, highlighting trends in earnings surprises.
Revenue & Expenses
CSBR has released its 2026 Q1 earnings report, with revenue of 13.99M, reflecting a YoY change of -0.47%, and net profit of -466.00K, showing a YoY change of -135.49%. The Sankey diagram below clearly presents CSBR's revenue sources and cost distribution.
Forecast
Wall Street Opinions
Price Target
Volume Profile
Trade Flow Insight
Seasonals
Community Forum
Loading...
Related News
No articles available
